Repare Therapeutics to Participate at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference

Rhea-AI Summary

Repare Therapeutics Inc. (Nasdaq:RPTX), a clinical-stage precision oncology company, announced its senior management's participation in a fireside chat at the 42^nd Annual Goldman Sachs Virtual Global Healthcare Conference on June 9 at 3:50 p.m. ET. The live webcast can be accessed via the Company’s website, with an archived replay available for 30 days. Repare focuses on synthetic lethality for developing targeted cancer therapies, including its lead candidate RP-3500, an ATR inhibitor in Phase 1/2 development. For more details, visit reparerx.com.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 42^nd Annual Goldman Sachs Virtual Global Healthcare Conference on Wednesday, June 9 at 3:50 p.m. Eastern Time.

A live webcast of the fireside chat can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for 30 days.

About Repare Therapeutics Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx^® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as eight other early-stage, pre-clinical programs. For more information, please visit reparerx.com.

SNIPRx^® is a registered trademark of Repare Therapeutics Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005095/en/

FAQ

When will Repare Therapeutics participate in the Goldman Sachs Virtual Global Healthcare Conference?

Repare Therapeutics will participate in the conference on June 9 at 3:50 p.m. Eastern Time.

Where can I watch the Repare Therapeutics fireside chat?

The fireside chat can be accessed live on Repare Therapeutics' Investor section of their website.

What is the focus of Repare Therapeutics' research?

Repare Therapeutics focuses on precision oncology using synthetic lethality to develop novel cancer therapies.

What are Repare Therapeutics' lead product candidates?

Repare's lead product candidates include RP-3500, an ATR inhibitor, and RP-6306, a PKMYT1 inhibitor, both currently in clinical development.

How long will the replay of the fireside chat be available?

The replay of the fireside chat will be archived on Repare Therapeutics' website for 30 days.